A phase Ib/IIa, randomised, double blind, parallel group, placebo controlled, multicentre study to assess the safety and efficacy of expanded Cx611 allogeneic adipose-derived stem cells (eASCs) for the intravenous treatment of adult patients with severe community-acquired bacterial pneumonia and admitted to the intensive care unit
Phase of Trial: Phase I/II
Latest Information Update: 16 Oct 2019
Price : $35 *
At a glance
- Drugs Cx 611 (Primary)
- Indications Sepsis
- Focus Adverse reactions
- Acronyms SEPCELL
- Sponsors TiGenix
- 18 Mar 2019 Planned End Date changed from 1 Oct 2020 to 1 Apr 2022.
- 18 Mar 2019 Planned primary completion date changed from 1 Mar 2019 to 1 Jul 2020.
- 12 Apr 2018 In Q1 2018, the independent Data Monitoring Committee (iDMC), recommended to continue the study with no changes in the protocol, after reviewing the safety and efficacy data from the first 20 randomized patients, according to a Tigenix media release.